Polaris AI Pharma Corp
041910
Company Profile
Business description
Polaris AI Pharma Corp is engaged in the production of raw pharmaceutical ingredients. It focuses on generic drugs and produces about 40 types of raw medicines, including asthma treatments, gastric ulcer treatments, and alcohol dependence treatments, and supplies them domestically and internationally.
Contact
25 Balangongdan-ro, Hyangnam-eup
Gyeonggi-do
Hwaseong-si
KORT: +82 318314800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
162
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.40 | 19.00 | -0.21% |
| CAC 40 | 8,166.21 | 61.11 | -0.74% |
| DAX 40 | 24,159.61 | 4.16 | 0.02% |
| Dow JONES (US) | 49,141.86 | 168.46 | -0.34% |
| FTSE 100 | 10,406.50 | 50.51 | -0.48% |
| HKSE | 25,978.07 | 62.87 | 0.24% |
| NASDAQ | 24,604.71 | 166.21 | 0.68% |
| Nikkei 225 | 59,716.18 | 575.95 | 0.97% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,125.65 | 17.25 | 0.24% |
| S&P/ASX 200 | 8,786.50 | 12.10 | -0.14% |
| SSE Composite Index | 4,079.90 | 13.35 | -0.33% |